Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-24-008120
Filing Date
2024-11-14
Accepted
2024-11-14 16:49:23
Documents
53
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR SEPT 2024 phio_i10q-093024.htm   iXBRL 10-Q 613221
2 CERTIFICATION phio_ex3101.htm EX-31.1 9195
3 CERTIFICATION phio_ex3102.htm EX-31.2 9199
4 CERTIFICATION phio_ex3201.htm EX-32.1 3948
5 CERTIFICATION phio_ex3202.htm EX-32.2 3865
  Complete submission text file 0001683168-24-008120.txt   3460737

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE phio-20240930.xsd EX-101.SCH 27820
7 XBRL CALCULATION FILE phio-20240930_cal.xml EX-101.CAL 32836
8 XBRL DEFINITION FILE phio-20240930_def.xml EX-101.DEF 114661
9 XBRL LABEL FILE phio-20240930_lab.xml EX-101.LAB 278356
10 XBRL PRESENTATION FILE phio-20240930_pre.xml EX-101.PRE 221951
55 EXTRACTED XBRL INSTANCE DOCUMENT phio_i10q-093024_htm.xml XML 415406
Mailing Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752
Business Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36304 | Film No.: 241463715
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)